Advances in Metastatic Prostate Cancer - M. Milowsky - 20160622
This lecture discusses some of the advancements in Metastatic Prostate Cancer such as the use of newer hormonal agents and Docetaxel chemotherapy against castration-sensitive metastatic prostate cancer. Learning Outcomes: • Discuss newer hormonal agents in the management of castration-resistant metastatic prostate cancer. • Examine a new role for Docetaxel chemotherapy in the management of castration-sensitive metastatic prostate cancer. • Compare other novel agents in the management of advanced prostate cancer. This lecture was presented as a part of the Medical and Surgical Oncology Series.
Matthew Milowsky MD
6/22/2016 3:30:00 PM

Mediasite Showcase
Mediasite's the trusted cornerstone of any campus or enterprise video strategy. Our unyielding commitment to all things video helps you transform education, training, communications and online events.
Webcasting Video Content Management Video Delivery Integration Services Mediasite Community
Powered By Mediasite - Enterprise Video Platform
Sonic Foundry